Trial Profile
A PHASE II STUDY OF BAY 43-9006 IN COMBINATION WITH WEEKLY GEMCITABINE FOR THE TREATMENT OF METASTATIC RCC EITHER UNSUITABLE FOR OR REFRACTORY TO PRIOR TREATMENT WITH CYTOKINES.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 May 2011
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 28 May 2011 New trial record